Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

Launched by NORTHWESTERN UNIVERSITY · Jul 17, 2012

Keywords

ClinConnect Summary

This clinical trial is looking at how blood, urine, and tissue samples can help doctors identify early signs of serious conditions like Chronic Kidney Disease (CKD), Acute Rejection (AR), and Hepatitis C (HCV) in patients who have received a liver transplant. These conditions can harm the body's ability to function well, so finding them early could lead to better treatments and possibly reduce the need for additional organ transplants in the future.

To participate in this study, you need to be at least 18 years old and have received a liver transplant from a living or deceased donor. Both men and women of all races are welcome to join, as long as they or their guardians can understand the study and agree to take part. If you choose to participate, you’ll provide samples of blood, urine, and tissue, which will be monitored throughout the study. This trial is currently recruiting participants, and your involvement could help improve care for future liver transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male and female recipients of all races, ≥18 years of age.
• • 2. Patients undergoing primary or subsequent living or deceased donor liver transplantation.
• • 3. Subject and/or guardian must be able to provide informed consent.
• • 4. Subject and/or guardian must be able to comply with the study protocol.
• Exclusion Criteria:
• • 1. Inability or unwillingness of a participant and/or guardian to provide informed consent.